{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05608252","nct_id":"NCT05608252","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05608252. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"During 28 day/4 week study cycle, participants will receive:\n\n* VS-6766 2x weekly for 3 out of the 4 week cycle\n* Abemaciclib 2x daily\n* Fulvestrant on day 1 of each study cycle (and day 15 of cycle 1 only)","label":"Phase 1 Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants will receive VS-6766 with abemaciclib and fulvestrant at the recommended phase II doses determined in the phase I portion of the study.","label":"Phase 2 Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":["Verastem, Inc.","Eli Lilly and Company"],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Breast Cancer","Hormone Receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer"],"enrollment":{"count":63,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"VS-6766","otherNames":[],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["Verzenio"],"type":"DRUG"},{"name":"Fulvestrant","otherNames":["Faslodex"],"type":"DRUG"}],"last_update":"2026-04-30","lead_sponsor":"Adrienne G. Waks","official_title":"A Single Arm Phase 1/2 Trial of Abemaciclib + Avutometinib (VS-6766) + Fulvestrant in Metastatic HR+/HER2- Breast Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1 Maximum tolerated dose (MTD)","timeFrame":"4 Weeks up to 2 years"},{"measure":"Phase 1 Recommended Phase II Dose (RP2D)","timeFrame":"4 Weeks up to 2 years"},{"measure":"Phase 2 Clinical benefit rate (CBR)","timeFrame":"6 months up to 3 years"}],"references":[],"start_date":{"date":"2023-02-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"VS-6766+Abema+Fulv in Met HR+/HER- BC","url":"https://clinicaltrials.gov/study/NCT05608252"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05608252"}